Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Padeliporfin VTP Shows Safety, Clinical Activity in Upper Tract Urothelial Cancer
June 7th 2025, 10:00am
The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.
Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC
June 6th 2025, 8:00pm
Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.
Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress
June 6th 2025, 1:00pm
European Hematology Association Congress
Experts highlight key abstracts to watch for at the 2025 EHA Congress.
RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma
June 6th 2025, 12:00pm
RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.
Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL
June 5th 2025, 4:30pm
Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.
Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC
June 5th 2025, 2:43pm
The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.
Highlighting the Key Takeaways From ASH 2024
June 5th 2025, 12:10pm
Unpacking Key Data from ASH 2024
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and minimal residual disease (MRD) monitoring are reshaping lymphoma treatment strategies, with emerging data showing promising outcomes for various lymphoma subtypes and ongoing trials exploring optimal sequencing of these therapies.
Treatment and Management of MM with Amyloidosis
June 5th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 are shaping the treatment and management of multiple myeloma (MM) with amyloidosis, emphasizing early diagnosis, novel therapies, and personalized treatment strategies to improve patient outcomes.
Recommendations For Future Clinical Trials in R/R MM
June 5th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma
June 4th 2025, 9:05pm
JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.
Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy
June 4th 2025, 7:25pm
Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.
ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma
June 4th 2025, 6:05pm
ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.
THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC
June 4th 2025, 4:50pm
THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.
BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma
June 4th 2025, 4:24pm
Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.
Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma
June 4th 2025, 12:00pm
Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.
NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis
June 3rd 2025, 10:58pm
The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
June 3rd 2025, 10:55pm
Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.
Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma
June 3rd 2025, 10:50pm
Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.
Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC
June 3rd 2025, 10:00pm
Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.
Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma
June 3rd 2025, 10:00pm
Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.